泓德基金：上周港股创新药板块表现亮眼

Group 1 - The domestic equity market experienced fluctuations last week, with major indices showing a weekly change within 1% and an average daily trading volume around 1.1 trillion yuan [1] - The North Securities 50 Index reached a historical high after breaking through 1500 points but then showed significant adjustment [1] - The A-share technology growth sector showed signs of weakening, while the Hong Kong innovative drug sector performed well [1] Group 2 - China's innovative drug sector has rapidly developed in recent years, with the number of active innovative drugs developed by Chinese companies reaching 3,575 by the end of 2024, ranking first globally [1] - Approximately 31% of innovative drug candidate molecules introduced by large multinational pharmaceutical companies in 2024 are from China, a significant increase from 0% in 2019 [1] - In April, the added value of high-tech manufacturing above designated size grew by 10%, indicating a clear trend towards high-end industrial development [1] Group 3 - The Chinese economy has shown resilience against external shocks, with a year-on-year increase of 2.4% in total goods import and export from January to April [1] - The bond market experienced overall fluctuations, with long-term bonds performing slightly better than short-term ones, and credit bond yields generally declining [2] - The market's response to recent interest rate changes, including a 10 basis point rate cut, has been limited, with future observations focusing on changes in funding supply post-tax period [2]